World’s Pneumonia Testing Market to See 9.91% CAGR through 2021, Predicts Infiniti Research in Its New Study Recently Added at MarketPublishers.com
28 Mar 2017 • by Natalie Aster
LONDON – Pneumonia is recognized as a complicated infection of the lower respiratory tract, which may start on/after an upper respiratory tract infection. More often pneumonia affects people with weak immune systems. Furthermore, it is more common in older people and children.
In the wake of enhancing health awareness along with rising disease incidence, the world’s market for pneumonia testing market is anticipated to follow an upward trend in the years to come. It will witness growth at a 9.91% CAGR during 2017-2021. Escalating awareness of early diagnosis and preventive measures will likely act as the key driver of the market growth. But, the market growth could be hindered by certain factors, for instance, limited detection capability and accuracy.
Leading vendors in the global arena include Abbott Molecular, Roche Molecular Diagnostics, bioMérieux, Thermo Fisher Scientific and Becton, Dickenson and Company (BD).
New topical study “Global Pneumonia Testing Market 2017-2021” elaborated by Infiniti Research offers a detailed guide to the present scenario in the world’s market for pneumonia testing. The report highlights the historical background of the market, covers the market dynamics and also examines the main factors influencing the market growth and development. The study gives access to important updated statistics, sheds light on the competitive environment and regulative framework, identifies top players and investigates the situation across the key regional markets for pneumonia testing. Furthermore, lucrative growth opportunities and key challenges are pointed out in the report. Future forecasts for the world’s pneumonia testing market is also at hand in this report.
For many other research reports prepared by this publisher follow to the Infiniti Research page.